Finance

Lists
Q2 2026 earnings • released • EPS beat +185.71% • Revenue beat +6.61%
See results
PBYI:NASDAQ
Puma Biotechnology Inc
$8.69
-2.47%
(-0.22) 1D
$8.69
0.00% (0.00)
After hours
Closed: Aug 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PBYI...
Open
$8.96
High
$8.96
Low
$8.55
Mkt. cap
448.58M
Avg. vol.
377.29K
Volume
437.95K
P/E ratio
18.22
52-wk high
$9.40
52-wk low
$3.71
EPS
$0.48
Beta
1.22
Shares outstanding
51.62M
No. of employees
179
Open
$8.96
High
$8.96
Low
$8.55
Mkt. cap
448.58M
Avg. vol.
377.29K
Volume
437.95K
P/E ratio
18.22
52-wk high
$9.40
52-wk low
$3.71
EPS
$0.48
Beta
1.22
Shares outstanding
51.62M
No. of employees
179
News stories
From web sources and news partners
Profile
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA. Wikipedia
About Puma Biotechnology Inc
CEO-
Employees179
Founded2007
HeadquartersLos Angeles, California, United States
SectorBiotechnology
Websitepumabiotechnology.com
Analyst ratings
Based on 1 analyst giving stock ratings to PBYI in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for PBYI in the last 3 months
Highest
Current $8.69
$6.00 (-30.96%)
Average
$6.00 (-30.96%)
Lowest
$6.00 (-30.96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Marc Frahm
TD Cowen
Hold
Maintained
$6.00
-31%
08/07/2026
Gena Wang
Barclays
Sell
Maintained
$2.00
-77%
11/07/2025
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.20 / $0.07
+185.71%beat
Revenue / Est. (USD)
56.50M / 53.00M
+6.61%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
54.48M
75.45M
44.81M
56.50M
Cost of goods sold
12.17M
23.13M
10.42M
12.48M
Cost of revenue
12.17M
23.13M
10.42M
12.48M
Research and development expenses
15.91M
16.84M
19.80M
18.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.82M
18.38M
18.42M
17.55M
Operating expense
32.73M
35.22M
38.22M
36.44M
Total operating expenses
44.90M
58.35M
48.64M
48.92M
Operating income
9.57M
17.11M
-3.83M
7.58M
Other non operating income
115.00K
143.00K
130.00K
9.00K
EBT including unusual items
9.24M
17.11M
-3.43M
8.24M
EBT excluding unusual items
9.24M
17.11M
-3.43M
8.24M
Income tax expense
399.00K
3.67M
326.00K
56.00K
Effective tax rate
4.32%
21.45%
-9.51%
0.68%
Other operating expenses
-
-
-
-
Net income
8.84M
13.44M
-3.75M
8.19M
Net profit margin
16.23%
17.81%
-8.37%
14.49%
Earnings per share
0.21
0.29
-0.04
0.20
Interest and investment income
1.04M
977.00K
1.00M
831.00K
Interest expense
-1.49M
-1.12M
-731.00K
-180.00K
Net interest expenses
-445.00K
-142.00K
271.00K
651.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
12.30M
18.96M
-1.24M
10.10M
Gain or loss from assets sale
-
4.00K
6.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps